News & Updates

Ketogenic diet reduces weight, raises aldosterone

20 Jul 2023

Adherence to ketogenic diets (KDs) results in weight reduction and increased aldosterone concentrations without worsening cardiometabolic risk factors, suggests a study.

Ketogenic diet reduces weight, raises aldosterone

20 Jul 2023

Oral health screening holds potential for diabetes prevention

20 Jul 2023

Basic indicators of oral health appear to be associated with the risk of developing diabetes, according to a study, suggesting the importance of oral health screening for preventing diabetes.

Oral health screening holds potential for diabetes prevention

20 Jul 2023

Tirzepatide induces weight loss in overweight/obese patients with T2D

20 Jul 2023 by

Treatment with once-weekly tirzepatide, a GIP* and GLP-1** receptor agonist, led to a substantial weight reduction among overweight or obese adults with type 2 diabetes (T2D), according to the phase III SURMOUNT-2 trial presented at ADA 2023.

Tirzepatide induces weight loss in overweight/obese patients with T2D

20 Jul 2023

Tirzepatide bests placebo, other glucose-lowering drugs at keeping lipid levels, waistline in check

19 Jul 2023

Treatment with tirzepatide is associated with better lipid profile and waist circumference outcomes compared with placebo and other glucose-lowering drugs, according to a study.

Tirzepatide bests placebo, other glucose-lowering drugs at keeping lipid levels, waistline in check

19 Jul 2023

Baseline HbA1c strongly predicts metformin failure

19 Jul 2023

Baseline glycated haemoglobin (HbA1c) is the most robust risk factor for metformin failure, reveals a study, noting that routinely available clinical data may be used to identify high-risk patients who may benefit from closer monitoring and earlier treatment intensification.

Baseline HbA1c strongly predicts metformin failure

19 Jul 2023

Anti-obesity therapies go beyond weight loss

19 Jul 2023 by

Weight loss strategies do not only provide therapeutic alternatives for obesity but may also hold promise in the management of type 2 diabetes (T2D) and NAFLD*.

Anti-obesity therapies go beyond weight loss

19 Jul 2023

Metformin discontinuation ups cardio-renal events in CKD patients with diabetes

18 Jul 2023 by

Putting an end to the use of metformin may lead to a higher risk of cardio-renal events in patients with diabetes and advanced chronic kidney disease (CKD), regardless of their cardiovascular disease (CVD) status, suggests a study presented at ADA 2023.

Metformin discontinuation ups cardio-renal events in CKD patients with diabetes

18 Jul 2023

Advanced liver fibrosis a red flag for poor outcomes in T2D

18 Jul 2023

Among individuals with type 2 diabetes (T2D), the risk of poor outcomes such as heart failure and hospitalizations is high in the presence of advanced liver fibrosis, according to a study.